Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Long-chain inulin phosphate monoester (PFXL) is a modified form of inulin, an oligosaccharide, developed as an additive to improve the quality of functional foods like red kidney bean steamed bread. It has demonstrated antidiabetic properties, including reducing fasting blood glucose and glycated serum protein, and improving oral glucose tolerance and blood lipid levels in diabetic mice. Additionally, it exhibits a protective effect against liver injury. Its application is aimed at modulating postprandial glucose homeostasis and blood lipid levels to reduce the risk of chronic metabolic disorders such as type 2 diabetes and obesity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on long-chain inulin phosphate monoester.